BioSpace News Archive

Ascendis Pharma A/S (Nasdaq: ASND) today announced the launch in Germany of SKYTROFA® (lonapegsomatropin), its growth hormone approved in the European Union for the once-weekly treatment of children and adolescents ages 3 to 18 years with growth failure due to insufficient endogenous growth hormone secretion (growth hormone deficiency, or GHD).

Sling Therapeutics, Inc. today announced Raymond Douglas, M.D., Ph.D., a world-leading clinician and thought leader in TED who has been integral to developing therapeutics for the disease, has been appointed as Chief Scientific Officer.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) today announced dosing of the first patient in its two-part, Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, for the treatment of nonalcoholic steatohepatitis (NASH), at The Pinnacle Edinberg/South Texas Research Institute in Edinburg, Texas, under the supervision of Principal Investigator, Dr. David Ramirez.

KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that the Company will participate in the Gilmartin Group Emerging Growth Company Showcase on September 21, 2023.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label extension of KAFTRIO®.

Merck (NYSE: MRK) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adults with non-small cell lung cancer (NSCLC), who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

The U.S. Food and Drug Administration announced it is taking new steps to further modernize its approach to evaluating and supporting the development of innovative animal and veterinary products, to increase regulatory flexibility, predictability and efficiency.

Up to an hour after their hearts had stopped, some patients revived by cardiopulmonary resuscitation had clear memories afterward of experiencing death, and had brain patterns while unconscious linked to thought and memory.

Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,100,000 shares of its common stock at a purchase price of $2.63 per share of common stock.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced that it issued inducement awards to four new employees.